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who likes to watch the birds and
seals on the estuary, or collect wild
mushrooms from the unspoilt
countryside near Dundee. The son
of a chemist who perfected the
printing ink technology for the
Sunday Times’ first colour magazine,
the young Cohen excelled in school
science but also spent long hours
bird-watching and pond dipping
around his home on the outskirts of
London. “Naively, I imagined that
biochemistry would be somewhere
in between.”
Today, he is an energetic, tireless
and very persuasive campaigner for
British biochemistry, colleagues say,
even encouraging students to publish
in British or European journals rather
than American ones. “Many of my
most cited papers have been
published in Current Biology, the
European Journal of Biochemistry and
FEBS Letters,” he notes. “Americans
are always looking for an excuse not
to read European journals. We are
cutting our own throats if we don’t
publish in them.”
Success has come through “hard
work, good luck and some intuition,”
Cohen says. These days, he reckons
his instant recall may be less sharp
than it was but his intuition is getting
better. He began to study protein
phosphorylation when it appeared to
be a mechanism linked only to
glycogen metabolism. “Now it seems
that protein phosphorylation
regulates everything.”
Cohen may have been lucky in
his early research directions but he
says he has also developed a gift for
spotting the unexpected. Five years
ago, “I had never done anything
with a pharmaceutical company,”
Cohen says. Now, long-term
industrial collaborations to generate
“huge batteries of specific kinase
and phosphatase inhibitors” are a
major goal, Cohen reckons. “This is
the way to solve cell signalling,” his
intuiton tells him, and some of the
pharmaceuticals giants are listening.
Gail Vines is a freelance science writer based
in Cambridge, UK.
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Zeneca
What is it famous for? At the moment,
for merging successfully with
Swedish drug makers Astra. By
joining forces with another mid-sized
pharmaceutical company, UK-based
Zeneca has leapfrogged to the
number one position in the league
table of pharmaceutical giants. The
combined company, called
AstraZeneca, has a 4.3% share of the
world’s US$251 billion prescription
drug market. The closest rivals
Merck, Glaxo Wellcome and Novartis
are all tied in second place, according
to 1998 sales figures.
How did Zeneca begin? Six years ago,
Zeneca was spun off from the drug
and agrochemical interests of the old
Imperial Chemical Industries (ICI).
Where is the new company based?
The corporate headquarters is in
London but research will be directed
from Sweden. Some 6,000 jobs are
expected to be lost over the next
three years, mainly in administration.
Why merge? Sir Richard Sykes, Glaxo
Wellcome’s chairman, summed it up
when he said that drug companies
come together “not to protect future
earnings growth but to increase
critical mass to outperform the
industry … the more money you can
put into research, the stronger the
company’s going to be.” AstraZeneca
has the second largest Research &
Development budget among the
drug companies, at US$1.9 billion,
behind both Glaxo Wellcome and
Merck, who are tied in first place.
What has Zeneca brought to the
partnership? A portfolio of cancer
drugs rivalled only by that of Bristol
Myers Squibb. Zeneca’s leading
oncology product, tamoxifen, is the
world’s most widely prescribed breast
cancer medication. Tamoxifen made
international headlines last year
when the US National Cancer
Institute announced — some said
prematurely (see Curr Biol 1998,
8:R328) — that the drug can halve
the risk of breast cancer in women
genetically predisposed to the
disease. But Zeneca isn’t just a
one-drug wonder. Each of the
following Zeneca products is the
world’s top seller in its category:
Diprivan, a general anesthetic;
Inderal, a β-blocker; and Zestril, used
to treat high blood pressure and heart
failure. Zeneca is also a top producer
of agrochemicals, a business it is
keeping in the merged company.
What about Astra’s medicine chest? Its
ulcer remedy, Losec, is the
best-selling prescription drug in the
world. Astra is also responsible for
Xylocaine, the most widely used
local anesthetic in the world.
Is this an equal partnership? Although
billed as a “merger of equals”,
Zeneca’s share price was stronger
than Astra’s at the time of the
merger. So Zeneca ends up as the
larger partner despite Astra’s drugs
business being of a similar size.
Who stands to gain? Merck. As part of
a divorce settlement that will end a
1982 joint venture between Astra
and Merck, AstraZeneca will pay
Merck US$1.7 billion up front, and a
minimum of US$4.7 billion in 2008.
Chiroscience (based in Cambridge,
UK) is also smiling. Zeneca has been
forced to give up rights to Chirocaine,
an anesthetic developed by
Chiroscience and under worldwide
licence to Zeneca, as its only direct
competition would be one developed
by Astra. AstraZeneca will have to
pay US$16 million to Chiroscience in
compensation, and still continue to
develop Chirocaine for commercial
launch this year.
Isn’t everybody doing it? As the names
of the major players reveal, the
pharmaceutical industry has a strong
tradition of mergers — now, even
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more drug companies are rushing
into bed with one another.
Rhône-Poulenc and Hoechst are
attempting to merge, and Glaxo
Wellcome is still looking for a
suitable partner after spurning
SmithKline Beecham last year and
Bristol Myers Squibb this year. For
the moment, only Zeneca and Astra
have succeeded in consummating
their affair.
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A new category of eye
movements in a small
fish
Kerstin A. Fritsches and
Justin Marshall
One of the main functions of the
oculomotor system in vertebrates and
most invertebrates is to keep the
image of the world relatively still on
the retina [1,2]. Eye re-locations are
often rapid gaze shifts or ‘saccades’
which move the eyes with high
velocity in order to minimise the
period during which the image is
destabilised [2]. Here, we describe
unusual drifting eye movements in a
small teleost fish, the sandlance
(Limnichthyes fasciatus). This animal
breaks the universal rule of image
stabilisation by showing large
postsaccadic drifts as part of its
normal oculomotor repertoire. 
When observing its environment,
the sandlance shows spontaneous
monocular saccades to eccentric eye
positions in order to locate prey
items in the water column above it
(Figure 1a); the two eyes are very
rarely synchronous. Its oculomotor
range is large, covering almost
180 degrees horizontally (rostral to
caudal) and 90 degrees vertically
(lateral to dorsal) (Figure 1c,d).
Between 20% and 40% of the
spontaneous saccades are followed
by postsaccadic drifts, especially
when the saccades are to very
eccentric eye positions (Figure 2a–c).
The drifts can cover up to 35 degrees
of angular distance and their average
speed is between 2 and 3 degrees per
second (Figure 2c), slower than that
of saccades by two orders of
magnitude (Figure 2b,c). Drifting
leads the eye from an eccentric
position back to a more relaxed
‘home position’, which is defined by
the most relaxed state of the eye
muscles. This indicates that the drift
is not visually driven but results from
a passive relaxation of the eye
muscles after a saccade. 
Sandlance eye drifts occur after
apparently spontaneous as well as
visually evoked saccades. During eye
movements elicited by rotation of
the environment (optokinesis), drifts
can be recorded at slow stimulus
speeds (our unpublished
observations). Sandlances can,
however, maintain stable fixation
when confronted with prey items in
the water column; this alternate
oculomotor strategy could perhaps
indicate a higher motivational state.
Other fish that also feed on small
planktonic prey, such as the pipefish
(Corythoichthys intestinalis), maintain
stable fixation after saccades in all
circumstances, and this is so for all
other vertebrates whose eye
movements have been studied
(Figure 1c; [1]). Stabilisation is
mediated by a very strong
optokinetic mechanism that uses
input of the world ‘panorama’ over a
large input visual field in order to
stabilise the eye. The eye drift in the
sandlance shows that this fish can
suppress the onset of this powerful
reflex, an ability unique among
vertebrates, although it is known to
occur, for other reasons, in a few
invertebrates [1]. 
Sandlances have a deep pit fovea
with the highest ganglion-cell
density that has been reported in a
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Figure 1
Drifts in the sandlance (Limnichthyes
fasciatus). (a) Head of a sandlance showing its
turret-like, very mobile eyes. (b) The onset,
direction and termination of a series of drifts
(arrows) superimposed on the eye of a
sandlance. From all eccentric positions the eye
drifts back to a more relaxed position, which
points forward and upwards. (c,d) Estimate of
the range of eye movements in the sandlance.
The illustration shows possible eye position
(grey) as measured from the centre of the pupil
mapped onto the visual space (globe):
(c) anterior view, (d) posterior view. The dots
represent data points of maximal eye position.
The darker shaded area indicates movements
into the contralateral visual field. 
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